AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01562457
Drug: activated recombinant human factor VII
RxNorm normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)
Trial: NCT02183363
Drug: BI 1356 - Tablet TFII
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183363
Drug: BI 1356 - Tablet iFF
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183363
Drug: BI 1356 - Tablet TFIIb
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01867255
Drug: venlafaxine ER (extended-release) 75 mg
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.
Trial: NCT00581191
Drug: SLV-351
RxNorm normalized name: SLV-334
DrugBank: SLV-334 (DB15356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLV-351 capsules taken once
Trial: NCT03753087
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg tablet
Trial: NCT01041859
Drug: Tapentadol extended release (ER)
RxNorm normalized name: tapentadol Extended Release Oral Tablet
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type= range, unit= mg, number= 100 to 250, form= tablet, route= oral use. Tapentadol ER optimal dose ranging between 100 mg and 250 mg twice daily for 15 weeks.
Trial: NCT00634062
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject in active active drug group will receive lamotrigine tablets 12.5 per day for the first week of the study. Dose of lamotrigine can be increased to 25mg per day during the second week of the study and may be increased each week thereafter for the next 9 weeks by 25mg per day. Subjects in active treatment group will receive lamotrigine for total of 12 weeks
Trial: NCT03691584
Drug: TP-6076
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The dose planned to be administered in this study is an iv infusion of 30 mg TP 6076 q24h for 4 consecutive days (starting on Day 1 and ending on Day 4).
Trial: NCT01167023
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally, once daily for 30 days.
Trial: NCT00418925
Drug: Dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg tablets; titrated over 14 days and 7 days steady dose
Trial: NCT00609765
Drug: Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Every 28 Days: Avastin 5mg/kg iv days 1 and 15
Trial: NCT00609765
Drug: Streptozocin
RxNorm normalized name: Streptozocin
DrugBank: Streptozocin (DB00428)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every 28 Days: Streptozocin 400mg/m2 iv bolus daily days 1-5
Trial: NCT00609765
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Premedication: Dexamethasone 20mg intravenously days 1-5
Trial: NCT00609765
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premedication: Ondansetron 16mg intravenously days 1-5
Trial: NCT01708993
Drug: Pemetrexed and Reolysin (and safety run-in)
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
Trial: NCT01708993
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks
Trial: NCT01708993
Drug: Docetaxel and Reolysin
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
Trial: NCT01708993
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks
Trial: NCT04557943
Drug: Prolotherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th.
Trial: NCT04557943
Drug: Sodium Hyaluronate
RxNorm normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronan sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
Trial: NCT01063660
Drug: Treosulfan
RxNorm normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 14 g/m²/d day -6 to -4
Trial: NCT00645307
Drug: Extended Release OROS® Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00410384
Drug: Belimumab 1 mg/kg
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
Trial: NCT00410384
Drug: Belimumab 10 mg/kg
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
Trial: NCT02475369
Drug: pancrelipase
RxNorm normalized name: pancrelipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00595361
Drug: salmeterol
RxNorm normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: salmeterol 50 micrograms twice daily for 2 weeks
Trial: NCT02462265
Drug: salvage therapy cytosar and mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days)
Trial: NCT00429702
Drug: ondansetron hydrochloride
RxNorm normalized name: Ondansetron Hydrochloride
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00080002
Drug: Pegamotecan
RxNorm normalized name: Pegamotecan
DrugBank: Pegamotecan (DB12842)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01133509
Drug: Gardasil
RxNorm normalized name: Gardasil
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5ml IM for three doses, Second and third dose to be given at 2 months and 6 months
Trial: NCT02424461
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 injection 1 g per day for 2 days
Trial: NCT02424461
Drug: Ofloxacine
RxNorm normalized name: Ofloxacine
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg/jour (200 mg/ jour in case of renal failure) for seven days
Trial: NCT02424461
Drug: Ofloxacine
RxNorm normalized name: Ofloxacine
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg/jour (200 mg/ jour in case of renal failure) for 14 days
Trial: NCT00169208
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m² IV, D1 each cycle during 4 cycles
Trial: NCT02424461
Drug: Placebo of ofloxacine
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo of ofloxacine for 7 days
Trial: NCT00640887
Drug: rifabutin in combination with efavirenz
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ia. arm 1a:~D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks);~Ib. arm 1b:~D4T/3TC/EFV(600mg)+INH/Rifabutin(600 mg OD 4 wks switch to 450 mg OD 4 wks);
Trial: NCT00640887
Drug: rifabutin in combination with nevirapine
RxNorm normalized name: Rifabutin
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IIa. arm 2a:~D4T/3TC/NVP(200mg)+INH/Rifabutin(300 mg OD 4 wks switch to 450 mg OD 4 wks);~IIb. arm 2b :~D4T/3TC/NVP(200mg)+INH/Rifabutin(450 mg OD 4 wks switch to 300 mg OD 4 wks);
Trial: NCT00309517
Drug: MAb 17-1A
RxNorm normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01654276
Drug: Febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One 40 mg tablet once a day for 6 months
Trial: NCT00169208
Drug: fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m²/day IV , D1 each cycle during 4 cycles
Trial: NCT00640887
Drug: rifabutin in combination with lopinavir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IIIa. arm 3a :~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg TPW 4 wks switch to 150 mg OD 4 wks);~IIIb. arm 3b:~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg OD 4 wks switch to 150 mg TPW 4 wks).
Trial: NCT03428334
Drug: Oral roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
Trial: NCT01880827
Drug: GIP-infusion
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blood flow and volume during infusion
Trial: NCT01880827
Drug: GLP-1
RxNorm normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood flow and volume during infusion
Trial: NCT00169208
Drug: mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/m² IV, D2-3-4 each cycle during 4 cycles
Trial: NCT02335268
Drug: N-Plate / romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions
Trial: NCT00201747
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC will be administered intravenously on day 1 (Arm A) and days 1 and 8 (Arm B)
Trial: NCT02578862
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01192295
Drug: Oxycodone HCl controlled-release tablets
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
Trial: NCT04682574
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mega dose is given to the selected critically ill patients
Trial: NCT00630539
Drug: Ospemifene 5 mg
RxNorm normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 tablet of ospemifene 5 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Trial: NCT02578862
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02293915
Drug: Sodium oligo-mannurarate 900mg
RxNorm normalized name: sodium mannuronate methylsilanol
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
Trial: NCT02637960
Drug: Fedovapagon 2 mg
RxNorm normalized name: Fedovapagon
DrugBank: Fedovapagon (DB11734)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One daily dose of 2 mg fedovapagon for 12 weeks
Trial: NCT00448123
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study Drug
Trial: NCT00630539
Drug: Ospemifene 15 mg
RxNorm normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 tablet of ospemifene 15 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Trial: NCT00630539
Drug: Ospemifene 30 mg
RxNorm normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 tablet of ospemifene 30 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Trial: NCT06417645
Drug: fixed propofol infusion 15 mg/kg/h until 1% BSR (burst suppression ratio)
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: after a slow induction with propofol to loss of consiousness (LOC), we proceed to give remifentanil TCI and rocuronium and intubate the patient. After 5 min we infuse 15 mg/kg/h until 1%BSR observe in the BIS monitor. Then we reduce the TCI LOC predicted concentration.
Trial: NCT03143816
Drug: Technosphere insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
Trial: NCT04405336
Drug: tab block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection of tab block to women who are doing cs
Trial: NCT04405336
Drug: PCA
RxNorm normalized name: PCA
DrugBank: Pidolic acid (DB03088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: giving women PCA
Trial: NCT00000320
Drug: Buprenorphine formulation: liquid vs. tablet
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: random assignment to liquid buprenorphine or tablet buprenorphine
Trial: NCT04411615
Drug: Omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rTG form Omega-3
Trial: NCT01892332
Drug: epidural block with lidocaine and fentanyl
RxNorm normalized name: Ivy Block
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.~Conversely, block success resulted in a reduction in concentration by 0.1%.
Trial: NCT02644018
Drug: Imidazolyl ethanamide pentandioic acid
RxNorm normalized name: IMIDAZOLYL ETHANAMIDE PENTANDIOIC ACID
DrugBank: Ingavirin (DB11944)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00910234
Drug: recombinant human erythropoietin (rhEpo)
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
Trial: NCT00910234
Drug: recombinant human erythropoietin (rhEpo)
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
Trial: NCT00349336
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7.5mg/kg iv on day 1 of each 3 week cycle
Trial: NCT00349336
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg/kg iv on day 1 of each 2 week cycle
Trial: NCT00003336
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
Trial: NCT02350361
Drug: Recombinant human endostatin
RxNorm normalized name: Recombinant human endostatin
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human endostatin 7.5mg/m2
Trial: NCT04569279
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban (Rovaltro®) is a novel oral anticoagulant that acts selectively, reversibly, and potently on activated Factor X (Factor Xa) inhibiting a critical point on the coagulation cascade. Rivaroxaban has excellent bioavailability, rapid onset of peak anticoagulation effect, and predictable pharmacokinetic and pharmacodynamic properties making routine laboratory monitoring and dose adjustments almost unnecessary (11). Rivaroxaban is an extensively studied drug and has received approvals for anticoagulation in several preventive and therapeutic indications (11). Now medical literature has some solid evidence that Rivaroxaban is comparable with other anticoagulants in terms of efficacy. Several studies imply that Rivaroxaban may have a lower risk of major bleeding (11). Several reports and small case-series (12,13) suggest that rivaroxaban may be beneficial as Warfarin in the treatment of cerebral venous thrombosis (CVT) with less or no major complications.
Trial: NCT03513588
Drug: PF-06865571
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, 50 mg, 14 days, every 12 hours
Trial: NCT03513588
Drug: PF-06865571
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, 300 mg, 14 days, every 12 hours
Trial: NCT04569279
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (Orfarin®) is the most popular vitamin K antagonist and is considered the standard of care in many venous and arterial anticoagulation indications with extensive clinical experience regarding its use. This inexpensive and effective drug has a narrow therapeutic window that is affected by diet changing and many drug interactions, making frequent monitoring with prothrombin time (PT)/international normalized ratio (INR) highly important.(14)
Trial: NCT01784380
Drug: Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04388774
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 40-minute intravenous infusion
Trial: NCT02736305
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once a day for 21 days in a 28 days cycle
Trial: NCT02957864
Drug: tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02957864
Drug: abacavir
RxNorm normalized name: Abacavir
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02483182
Drug: Acyclovir cream 5%
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00723320
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin 10mg/d
Trial: NCT00419068
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no